Neoadjuvant immunotherapy prior to surgery is safe and feasible in early lung cancer
Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.
Go to Source